Successful recovery of severe hypothermia with minimally invasive central catheter.

BACKGROUND: Severe hypothermia can result in malignant arrhythmias or cardiac arrest and require invasive central rewarming modalities due to a core body temperature < 28 °C. Difficult rescue missions can make continuous CPR challenging, but the decrease in oxygen consumption at these low temperatures allows for successful recovery despite the delay. Although other active warming techniques, such as peritoneal lavage, intravascular warming catheter, and renal replacement therapy can be beneficial, the consensus statements recommend extracorporeal life support as the preferred rewarming method. CASE PRESENTATION: A 42-year-old female was found in a pond after presumed exposure for 30-40 min with an outside temperature of 17 °F (-8 °C) and was found to be in ventricular fibrillation. ACLS protocol was then initiated. At the hospital, she was intubated and sedated with continuous CPR during multimodal rewarming, including active internal via the ZOLL Icy catheter. One hour after rewarming, with core temperature above 29 °C, she was defibrillated and achieved ROSC. As she continued to warm, she made purposeful movement and was warmed and maintained at euthermia. She was initiated on antibiotics due to aspiration concerns and titrated off vasopressors with extubation on day 2 of hospitalization. She had mild complaints of extremity numbness and chest pain from compressions prior to discharge on hospitalization day 4. CONCLUSIONS: This case has a successful resuscitation of severe hypothermia associated with cardiac arrest. The patient was warmed at greater than 4 °C/h with a less invasive, quicker and potentially more available approach to warming. With equipment improvements, the ability to provide prolonged CPR while rewarming may suggest that transferring to an extracorporeal life support center is not necessary.

A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration.

Orolingual angioedema is a rare adverse effect of tissue plasminogen activator (tPA), with an incidence of 1% to 5%. There are currently no published reports describing resolution of tPA-induced orolingual angioedema with complement inhibitor therapy. A 72-year-old man receiving home angiotensin-converting enzyme inhibitor therapy presented to the emergency department with newly developed orolingual angioedema after treatment with tPA for acute ischemic stroke. Therapy was initiated with intravenous methylprednisolone 125 mg, famotidine 20 mg, and diphenhydramine 50 mg, without significant improvement. Because of increased concern for airway protection, plasma-derived C1 esterase inhibitor was administered. Concerns about progressive and airway-threatening orolingual angioedema subsided 2 hours after administration, and invasive airway maneuvers were avoided. Orolingual angioedema is an infrequent, severe adverse effect of tPA for treatment of acute ischemic stroke. Complement inhibitors may be an additional therapeutic option for patients presenting with orolingual angioedema with potential airway compromise that is refractory to standard anaphylactic therapies.

The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban: A Multicenter Evaluation.

PURPOSE: Adoption of the target-specific oral anticoagulants (TSOACs) has been slow; accordingly, lack of guidance for emergent reversal confounded by the need for "direct" reversal agents has contributed significantly to warfarin entrenchment in the medical community. The purpose of this analysis is to provide real-world experiences regarding the management of the hemorrhaging patient secondary to dabigatran and rivaroxaban. METHODS: Retrospective review of patients admitted with a hemorrhage secondary to dabigatran or rivaroxaban were evaluated. Descriptive statistics were utilized for analysis. RESULTS: Four hundred forty-four patients were screened for inclusion into the study; notably, 419 (94%) of the patients were excluded because the bleed was secondary to warfarin therapy. Of those included in this analysis (n = 25), gastrointestinal bleeding accounted for 21 events (84%), followed by intracranial (n = 2; 8%) and epistaxis (n = 2; 8%). Two patients (8%) expired during admission and 6 patients (24%) expired within 6 months after discharge from the hospital. Three (12%) minor bleeds, 7 (28%) major bleeds, and 15 (60%) life-threatening bleeds were identified. Minor bleeds required careful monitoring, supportive care, and cessation of anticoagulation therapy, whereas increasing severity required multiple interventions with prothrombin complex concentrate, recombinant activated factor 7, fresh frozen plasma, packed red blood cells, cryoprecipitate, and platelets. CONCLUSION: The approach to the management of bleeding events borne from TSOACs has proven to be very heterogeneous. In the midst of this observation period, these facilities developed protocols, which created a stratification of bleeds and a more regimented approach to managing them. Although bleeding is less with new agents, the creation of pathways/algorithms for the management of TSOACs and education regarding clinical decision-making may be beneficial for the expeditious and appropriate management when these events arise.